PharmTech Weekly Roundup—May 29, 2026

This week's pharma news reflects an industry navigating on multiple fronts simultaneously. Regulatory timelines are tightening, strategic capital is moving into new therapeutic categories, and long-standing operational gaps—in manufacturing workforces and supply chain data—are demanding real solutions.

In news this week, the FDA has extended its review of AstraZeneca's new drug application for the company’s next-generation oral selective estrogen receptor degrader for the treatment of advanced breast cancer. The delay follows an advisory committee vote against the application and reflects the agency's continued strain under budget-driven resource constraints. The FDA's approval delay signals both the clinical complexity of novel treatment-switching strategies and the real-world impact of reduced agency review capacity on drug approval timelines.

Eli Lilly announced the acquisition of three vaccine-focused biotechs—Curevo, LimmaTech Biologics, and Vaccine Company—for up to $3.83 billion. The deals, its 10th acquisition of 2026, target vaccines that may prevent not only infections but downstream conditions including neurological disease and certain cancers. Lilly is using GLP-1-driven cash flows to make a deliberate strategic pivot into upstream infectious disease prevention—signaling that the vaccine space is regaining credibility as a long-term pharma investment.

On PharmTech.com this week, the second installment of the Pharma Fundamentals video series features Dr. Christine Allen of Intrepid Labs and Dr. Andy Lewis of Quotient Sciences as they breakdown how AI and machine learning are being applied across the drug development lifecycle—from compound screening and ADMET prediction to digital twins in manufacturing —while noting that data quality, domain-specific model training, and regulatory acceptance remain the primary barriers to full-scale deployment. AI is no longer a pilot project—it is being integrated across the entire development lifecycle—but success depends on fit-for-purpose data infrastructure and regulatory frameworks that can validate AI-generated evidence.

An analysis by Brian Drapeau, founder of GxPFrame, identifies training as the most under appreciated constraint in cell and gene therapy manufacturing. At facilities with 40% annual turnover, replacement and retraining costs can approach $3 million per year, and LMS-based check-the-box programs are falling short of 21 CFR Part 211.25 GMP competency standards for complex CGT operations. CGT manufacturers need to replace checkbox training with competency-based qualification frameworks that produce audit-ready evidence of demonstrated capability — not just completed e-learning modules.

In an interview with PharmTech,Toragen CEO Sandra Coufal outlines the development path for TGN-S15, a novel HPV-targeted therapy for precancerous cervical disease. The program is backed by a Gates Foundation grant and guided by a scientific advisory board anchored by the world's leading authority on the HPV E5 protein, with access to a rare precancerous cervical cell line from the University of Cambridge.

Toragen's TGN-S15 program demonstrates how smaller biotech companies can accelerate development in high-unmet-need areas by strategically assembling world-class scientific expertise and mission-aligned funding.

European Regulatory Watch columnist Cheryl Barton explains how the European Parliament and Council reached a provisional agreement on the Critical Medicines Act on May 12th. The legislation targets roughly 300 medicines deemed critical to European public health — including antibiotics, insulin, and vaccines — and shifts procurement criteria beyond price alone to reward EU-based manufacturing, supply chain diversification, and environmental standards. The Critical Medicines Act is one of the most consequential industrial policy shifts in European pharma in decades, and manufacturers who have not yet mapped their supply chain exposure to its new procurement criteria should begin doing so now.

And finally, Manish Garg explains that, with full DSCSA enforcement now in effect, pharma companies are sitting on billions of EPCIS serialization events annually — but most are leaving that data underused. Garg argues the industry must evolve serialization infrastructure from a compliance requirement into an operational intelligence platform capable of preventing quarantines, managing partner exceptions, and reducing supply chain fragility. Post-DSCSA, pharmaceutical serialization must move beyond compliance into active operational intelligence — leveraging EPCIS data to prevent disruptions, not just document them.

Be sure to read these articles and watch the interviews on PharmTech.com.